Efficacy and safety of Yindan Xinnaotong capsule combined with atorvastatin in patients with stable angina pectoris

Li Xin-xing; Li Kui; Kang Ni-na; Zhang Qian

doi:10.3969/j.issn.1672-8157.2024.06.032

Abstract：Objective To explore the efficacy and safety of Yindan Xinnaotong soft capsule combined with atorvastatin in treatment of stable angina pectoris (SAP). Methods A total of 118 patients with SAP admitted to Yibin Third People' s Hospital from February 2022 to February 2024 were selected as the research subjects and divided into the study group (treated with Yindan Xinnaotong) and the control group (treated with atorvastatin) according to the envelope method,with 59 in each group. All the patients in both groups were given con-ventional treatment. The patients in the control group received atorvastatin treatment while those in the study group were treated with Yindan Xinnaotong soft capsule based on the regimen in the control. The clinical efficacy 6 weeks after treatment,frequency and duration of angina pectoris attack,cardiac function (left ventricular ejection fraction (LVEF),left ventricular end-systolic diameter (LVESD),left ventricular end-diastolic diameter (LVEDD),stroke volume (SV),cardiac index (CI)),blood lipids and serum biochemical indicators (C-reactive protein (CRP),neutrophil-to-lymphocyte ratio (NLR),brain natriuretic peptide (BNP)) before and after treatment and adverse re-actions were compared between the two groups. Results The total clinical effective rate was 94.92％ (56/59) in the study group,which was higher than that of 83.05％ (49/59) in the study group (x2=4.236,P<0.05). After treatment for 6 weeks,the frequency and duration of angina pectoris attack in the two groups were (3.44±0.49) times/week,(4.46±0.57) times/week,(2.72±0.37) min/time,(3.31±0.44) min/time,which were higher than those before treatment ((6.52±0.71) times/week,(6.34±0.65) times/week,(5.32±0.65) min/time,(5.49±0.74) min time) and they were significantly lower in the study group than in the control (P<0.05). After treatment,LVEF,SV and CI in the two groups were (58.37±4.67)％,(54.37±5.03)％,(73.48±7.13) mL,(70.22±6.18) mL,(4.67±0.23) L·(min·m2)-1,(4.11±0.31) L·(min·m2)-1,which were higher than those of (48.61±3.12)％,(49.14±3.27)％,(63.72±6.31) mL,(64.13±5.66) mL,(2.41±0.61) L·(min·m2)-1,(2.48±0.42) L·(min·m2)-1 before treatment (all P<0.05). However,the LVESD and LVEDD ((34.37±2.63) mm,(39.56±3.11) mm,(51.37±4.39) mm,(56.38±4.51) mm) were lower than ((46.21±3.47 mm,(45.87±3.22) mm,(62.19±5.22) mm,(61.76±5.37) mm) before treatment (all P<0.05),and the LVEF,SV and CI in the study group were higher ( all P<0.05) while the LVESD and LVEDD were lower than those in the control (all P<0.05). Serum levels of TC,TG and LDL-C in both groups after treatment ((4.17±0.71) mmol·L-1,(4.62±0.82) mmol·L-1,(2.87±0.54) mmol·L-1,(3.22±0.43) mmol·L-1 and (2.51±0.43) mmol·L-1,(2.81±0.48) mmol·L-1) were lower than those before treatment ((5.41±1.21) mmol·L-1,(5.56±1.16) mmol·L-1,(4.36±0.86) mmol·L-1,(4.24±0.76) mmol·L-1,(3.12±0.86) mmol·L-1,(3.07±0.77) mmol·L-1) (all P<0.05) while the HDL-C ((2.12±0.51) mmol·L-1,(1.73±0.46) mmol·L-1) was higher than that before treatment ((1.05±0.33) mmol·L-1,(1.12±0.32) mmol·L-1) (all P<0.05),and the levels of TC,TG and LDI-C in the study group were lower (all P<0.05) while the HDL-C level was higher than in the control (P<0.05). Serum CRP,NLR and BNP levels in both groups ((5.06±1.03) mg·L-1,(6.43±1.12) mg·L-1,(1.63±0.42)％,(2.01±0.43)％,(105.28±12.31) pg·L-1,(126.37±13.25) pg·L-1) were lower than those before treatment ((8.66±1.33) mg·L-1,(8.74±1.45) mg·L-1,(2.87±0.47)％,(2.92±0.58)％,(231.46±21.22) pg·L-1,(233.38±20.16) pg·L-1),and they were lower in the study group than in the control (all P<0.05). Conclusion Yindan Xinnaotong soft capsule combined with atorvastatin has significant efficacy in treatment of SAP since it can regulate blood lipids and improve vascular inflammation and cardiac function.